Table 3.
Real-life application—primary tumours
| Category | Subcategory | HCC (n = 422) | ICC (n = 120) | All (n = 542) |
|---|---|---|---|---|
| Time since primary diagnosis (days) | Median | 188 | 201 | 191 |
| Q1, Q3 | 71, 590 | 65, 468 | 70, 652 | |
| Missing | 4 (0.9%) | 2 (1.7%) | 6 (0.1%) | |
| Intention of treatmentc | Ablation | 17 (4.0%) | 7 (5.8%) | 24 (4.4%) |
| Bridge to liver surgery | 3 (0.7%) | 3 (2.5%) | 6 (1.1%) | |
| Bridge to liver transplant | 23 (5.5%) | 2 (1.7%) | 25 (4.6%) | |
| Downsizing / down-staging | 137 (32.5%) | 25 (20.8%) | 162 (29.9%) | |
| Palliative | 242 (57.3%) | 83 (69.2%) | 325 (60.0%) | |
| Prior TARE hepatic procedures | Yes | 189 (44.8%) | 41 (34.2%) | 230 (42.4%) |
| No | 233 (55.2%) | 79 (65.8%) | 312 (57.6%) | |
| Surgical (any)a | 72 (17.1%) | 32 (26.7%) | 104 (19.2%) | |
| Ablation (any) | 62 (14.7%) | 7 (5.8%) | 69 (12.7%) | |
| TACE (any) | 97 (23.0%) | 2 (1.7%) | 99 (18.3%) | |
| Vascular (any) | 15 (3.6%) | 1 (0.8%) | 16 (3.0%) | |
| Abdominal radiotherapy (any) | 7 (1.7%) | 5 (4.2%) | 12 (2.2%) | |
| Prior systemic therapy | Yes | 45 (10.7%) | 73 (60.8%) | 118 (21.8%) |
| No | 377 (89.3%) | 47 (39.2%) | 424 (78.2%) | |
| Concomitant chemotherapyb | Yes | 32 (7.6%) | 11 (9.2%) | 43 (7.9%) |
| No | 390 (92.4%) | 109 (90.8%) | 499 (92.1%) | |
| Post-TARE systemic therapy | Yes | 125 (29.6%) | 45 (37.5%) | 170 (31.4%) |
| No | 262 (62.1%) | 63 (52.5%) | 325 (60.0%) | |
| Missingd | 35 (8.3%) | 12 (10.0%) | 47 (8.7%) | |
| Post-TARE hepatic procedures | Yes | 80 (19.0%) | 20 (16.7%) | 100 (18.4%) |
| No | 307 (72.7%) | 88 (73.3%) | 395 (72.9%) | |
| Missingd | 35 (8.3%) | 12 (10.0%) | 47 (8.7%) | |
| Surgical (any)a | 3 (0.7%) | 4 (3.3%) | 7 (1.3%) | |
| Ablation (any) | 11 (2.6%) | 4 (3.3%) | 5 (2.8%) | |
| TACE (any) | 34 (8.1%) | 1 (0.8%) | 35 (6.5%) | |
| Vascular (any) | 7 (1.7%) | 2 (1.7%) | 9 (1.7%) | |
| Abdominal radiotherapy (any) | 13 (3.1%) | 6 (5.0%) | 19 (3.5%) |
aPatients can have multiple prior and post-TARE hepatic procedures
bConcomitant if systemic therapy start date is within 4 weeks of first TARE treatment start date and up to 8 weeks after first TARE end date (where end date is within 42 days of first TARE in case of two sessions)
cIntention of TARE is for first treatment
dMissing data include data from patients that were lost to follow up or deceased before the first follow-up could be included (n = 47)